Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523320 | 0.89 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL16861397 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL838252 | 0.86 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL8641593 | 0.86 | ALDH1A1 (0.54) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL2301205 | 0.86 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL14645833 | 0.84 | ALDH1A1 (0.53) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL6562864 | 0.83 | MAOB (0.46) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL16959889 | 0.82 | ALDH1A1 (0.50) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL5152240 | 0.81 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL2459449 | 0.81 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4638447-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024188906-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2024-09-19 | — | — | WO | disclosed |
| EP-4428134-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| US-7893067-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-7893067-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-20110039862-A1 | Protease Inhibitors | MEDIVIR AB (SE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039862-A1 | Protease Inhibitors | MEDIVIR AB (SE) | 2011-02-17 | — | — | US | disclosed |
| WO-2010034789-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034788-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-04-01 | — | — | WO | disclosed |
| US-20090023748-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023748-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000877-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008114054-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINB1, SERPINE1 | KDM4E 4608/4885ALDH1A1 217/4885HSD17B10 1103/4885 |
| US-20090023748-A1 | Cysteine Protease Inhibitors | CTSK, CTSL, CTSV | KDM4E 412/4885ALDH1A1 3386/4885HSD17B10 3744/4885 |
| US-20110039862-A1 | Protease Inhibitors | CTSK, CTSF, CTSS | KDM4E 3808/4885ALDH1A1 3165/4885HSD17B10 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.